Elevance Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Elevance Health (ELV).

Price Target Range — 8 Quarters

Analyst Consensus — 20 Analysts

14Buy

6Hold

Consensus RatingBuy# Analysts20Avg. Consensus PT$450Upside to Avg. PT+9.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 27, 2026	Wells Fargo	Stephen Baxter	PT Raise	Overweight	$473→$492
Oct 23, 2026	TD Cowen	Ryan Langston	PT Raise	Buy	$465→$495
Oct 22, 2026	UBS	A.J. Rice	PT Raise	Buy	$460→$523
Oct 22, 2026	Guggenheim	Jason Cassorla	PT Raise	Buy	$460→$485
Oct 22, 2026	Morgan Stanley	Erin Wright	PT Raise	Equal-Weight	$404→$449
Oct 22, 2026	RBC Capital	Ben Hendrix	PT Raise	Sector Perform	$424→$455
Oct 22, 2026	Barclays	Andrew Mok	PT Raise	Overweight	$469→$472
Oct 22, 2026	Baird	Michael Ha	PT Raise	Neutral	$393→$406
Oct 12, 2026	Guggenheim	Jason Cassorla	PT Raise	Buy	$455→$460
Oct 7, 2026	Barclays	Andrew Mok	PT Raise	Overweight	$457→$469
Jul 17, 2026	Bernstein	Lance Wilkes	PT Raise	Outperform	$482→$488
Jul 17, 2026	Leerink Partners	Whit Mayo	PT Raise	Market Perform	$364→$395
Jul 16, 2026	RBC Capital	Ben Hendrix	PT Cut	Sector Perform	$439→$424
Jul 16, 2026	Wells Fargo	Stephen Baxter	PT Cut	Overweight	$492→$473
Jul 16, 2026	Guggenheim	Jason Cassorla	PT Raise	Buy	$399→$455
Jul 16, 2026	Barclays	Andrew Mok	PT Cut	Overweight	$480→$457
Jul 16, 2026	Baird	Michael Ha	PT Raise	Neutral	$331→$393
Jul 14, 2026	TD Cowen	Ryan Langston	PT Raise	Buy	$400→$465
Jul 14, 2026	Truist Securities	David Macdonald	PT Raise	Buy	$450→$475
Jul 13, 2026	Wells Fargo	Stephen Baxter	PT Raise	Overweight	$391→$492

Analyst Ratings News

PRO
Wells Fargo Maintains Overweight on Elevance Health, Raises Price Target to $492

Wells Fargo analyst Stephen Baxter maintains Elevance Health (NYSE:ELV) with a Overweight and raises the price target from $473 to $492.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Elevance Health, Raises Price Target to $495

TD Cowen analyst Ryan Langston maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $465 to $495.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Elevance Health, Raises Price Target to $523

UBS analyst A.J. Rice maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $460 to $523.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $485

Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $460 to $485.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Elevance Health, Raises Price Target to $449

Morgan Stanley analyst Erin Wright maintains Elevance Health (NYSE:ELV) with a Equal-Weight and raises the price target from $404 to $449.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Elevance Health, Raises Price Target to $455

RBC Capital analyst Ben Hendrix maintains Elevance Health (NYSE:ELV) with a Sector Perform and raises the price target from $424 to $455.

Benzinga Newsdesk

Elevance Health Inc

Elevance Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wells Fargo Maintains Overweight on Elevance Health, Raises Price Target to $492

PRO
TD Cowen Maintains Buy on Elevance Health, Raises Price Target to $495

PRO
UBS Maintains Buy on Elevance Health, Raises Price Target to $523

PRO
Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $485

PRO
Morgan Stanley Maintains Equal-Weight on Elevance Health, Raises Price Target to $449

PRO
RBC Capital Maintains Sector Perform on Elevance Health, Raises Price Target to $455

People Also Watch

People Also Watch

Elevance Health Inc

Elevance Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWells Fargo Maintains Overweight on Elevance Health, Raises Price Target to $492

PROTD Cowen Maintains Buy on Elevance Health, Raises Price Target to $495

PROUBS Maintains Buy on Elevance Health, Raises Price Target to $523

PROGuggenheim Maintains Buy on Elevance Health, Raises Price Target to $485

PROMorgan Stanley Maintains Equal-Weight on Elevance Health, Raises Price Target to $449

PRORBC Capital Maintains Sector Perform on Elevance Health, Raises Price Target to $455

People Also Watch

People Also Watch

PRO
Wells Fargo Maintains Overweight on Elevance Health, Raises Price Target to $492

PRO
TD Cowen Maintains Buy on Elevance Health, Raises Price Target to $495

PRO
UBS Maintains Buy on Elevance Health, Raises Price Target to $523

PRO
Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $485

PRO
Morgan Stanley Maintains Equal-Weight on Elevance Health, Raises Price Target to $449

PRO
RBC Capital Maintains Sector Perform on Elevance Health, Raises Price Target to $455